Sanofi’s ready to say farewell to Bangladesh, local media reports, despite pleas from government officials to stay put.
After more than 60 years in the country, the drugmaker has notified the Bangladesh Chemical Industries Corporation (BCIC)—which owns about 20% of the company’s local outfit—that it’s planning to exit, the Financial Express reports.
BCIC officials are pressing Sanofi to stay, but the company’s planning to move out for strategic reasons, The Daily Star reports. It could continue supplying medicines to Bangladesh through imports, according to the reports.
As of 2016, Sanofi was the largest pharma company in Bangladesh with more than 1,200 employees there, according to a paper published in the International Journal of Business and Management. It operates a plant in Tongi, according to an SEC filing, and maintains a corporate office in Dhaka.
To make its exit, Sanofi aims to sell its approximately 55% share in the local company. The Bangladeshi government owns the remaining 45%, according to reports.
The move follows GlaxoSmithKline’s Bangladesh exit last year; that company found the market “not sustainable,” according to the Financial Express report.
For Sanofi, the reported exit also comes after the company sold its generics outfit Zentiva to Advent International for $2.2 billion last year. The generics company has a global manufacturing footprint and about 3,000 employees. Earlier this month, Advent bought a Sanofi manufacturing plant in India for $36.5 million.
If Sanofi does in fact exit Bangladesh, it may well be one of the first moves authorized by new Sanofi CEO Paul Hudson. He took up the role at the beginning of this month, replacing Olivier Brandicourt, who retired. During his four-year CEO stint, Brandicourt worked to cut costs and refocus the company around five business units.
A Sanofi representative didn’t immediately comment on the reports.
By Eric Sagonowsky
Source: Fierce Pharma
The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.
US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.
EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.
